Navigation Links
Sponsor of Drug Bill Rejected by CA Senate Today Changed Its Name After Privacy Violations
Date:5/22/2008

SANTA MONICA, Calif., May 22 /PRNewswire-USNewswire/ -- The California Senate rejected a bill today sponsored by a drug marketing firm that was forced to change its name after privacy violations. See Washington Post coverage below.

The bill, SB 1096 (Calderon), which was granted a second chance to pass the Senate and will be voted on again next week, would create a loophole in existing law which bars the sharing of private medical information -- including a patient's illnesses and prescribed medications -- without a patient's prior consent.

"The California Constitution protects the privacy of all Californians. At a minimum, patients must be asked and give consent before their medical records are traded or sold. As personal information -- medical, financial and domestic -- becomes an increasingly available and valuable commodity for the corporations that buy and sell it, consumers are more vulnerable to unscrupulous marketers, identity thieves and corrupt corporations," said Jerry Flanagan, Health Care Policy Director for Consumer Watchdog. "We urge the Senate to continue to oppose this measure unless it is amended to require a patient's informed consent prior to the transfer of private medical information."

In the last 2 years, the bill author, Senator Ronald Calderon, has received at least $21,690 from drug companies and others that will benefit from the legislation.

The bill would allow companies like Adheris, the bill sponsor, to access patients' prescription drug purchases, putatively only for the purpose of communicating with patients to increase "adherence" to the scheduled regimen. The bill is premised on the idea that mailed reminders will help ensure that patients take their medications. The bill sponsor provides no evidence to support the claim. Further, if in fact a reminder to take medication was the goal of the bill, the pharmacy itself could send the reminder without necessitating the transfer of private medical data to a third-party business.

"The bill sponsor is a marketing company employed by drug manufacturers to increase the sales of prescription drugs and has no place in 'informing' patients about their illness without their prior consent. This seemingly benign 'service' violates a patient's right to control his or her personal medical information," said Flanagan.

SB 1096 raises the following concerns:

1. There is no way in many instances for Adheris to know exactly why a medication has been prescribed or how a doctor expects it to be taken.

2. Adheris' advice about how long a medication should be taken may conflict with that of the physician who actually knows the patient, and who may wish to stop the medication or switch to a different medication. If such conflicts occur for even a short time, they may reduce patients' confidence in their doctor.

3. The patient's doctor may want him or her to report all significant side effects (particularly among the elderly, weak or immune-compromised), not just those that Adheris may describe as serious or life-threatening.

4. Further, medical records are often coded with a patient's Social Security number. Information aggregators that get access to medical records could use the Social Security number to combine medical information with a wide range of information already available, including credit information and lists of credit card purchases and bank account balances. The resulting data file would be immensely valuable to companies looking to market products or, in the case of insurers or even mortgage lenders, deny a policy or loan based on combined health and financial data. The digital dossier, maintained without direct government oversight, would also be an attractive target for hackers and identity thieves.

Washington Post coverage of Adheris' name change and privacy violations:

After Privacy Flap, a New Name; Other Changes at Prescription-Reminder Firm

Less Clear: http://www.consumerwatchdog.org/patients/articles/?storyId=20325

Ultimately, a Healthy Decision At Giant and CVS Pharmacy: http://www.consumerwatchdog.org/patients/articles/?storyId=20326

CVS Also Cuts Ties To Marketing Service; Like Giant, Firm Cites Privacy on

Prescriptions: http://www.consumerwatchdog.org/patients/articles/?storyId=20327

EDITORIAL - When Private Means Private:http://www.consumerwatchdog.org/patients/articles/?storyId=20328

Giant Food Stops Sharing Customer Data; Prescription-Marketing Plan Drew Complaints: http://www.consumerwatchdog.org/patients/articles/?storyId=20329

Prescription Sales, Privacy Fears; CVS, Giant Share Customer Records With Drug Marketing Firm: http://www.consumerwatchdog.org/patients/articles/?storyId=20331


'/>"/>
SOURCE Consumer Watchdog
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Aflac to be Primary Sponsor of Carl Edwards and the No. 99 Ford Fusion
2. C5 Medical Werks Joins in Sponsoring SpineWeek 2008 in Geneva, Switzerland
3. UPMC for Life is Pennsylvania Sponsor for National Senior Health & Fitness Day
4. Duane Reade Announces Proud Sponsorship of AIDS Walk New York
5. West Coast Bank Sponsors Reach the Bridge Run to Benefit the American Lung Association of Oregon
6. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
7. Aflac Announces Title Sponsorship of Outdoor Games
8. Ferring Pharmaceuticals EUFLEXXA(R) to Serve as a Sponsor for the Babolat World Tennis Classic
9. Target Data Research Becomes the Largest Sponsor for the Annual 2008 Steppin Forward Benefit
10. Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials
11. West Coast Bank Sponsors Reach the Beach Cycling Fundraiser to Support the American Lung Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
Breaking Medicine Technology: